search
Back to results

eMotiph: E-mental Health Solution for Patients With Schizophrenia

Primary Purpose

Schizophrenia

Status
Completed
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
eMotiph
Sponsored by
Grupo Pulso
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional device feasibility trial for Schizophrenia focused on measuring mHealth, Treatment resistent schizophrenia

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age between 18-55 years old.
  • Diagnosis of schizophrenia following the Diagnostic and Statistical Manual of Mental Disorders-5 criteria.
  • Meet criteria for treatment-resistant schizophrenia.
  • Used to information and communication technology and with the physical capability to use them.

Exclusion Criteria:

  • Meet criteria for remission according to the Remission of Schizophrenia Working Group (Andreasen et al., 2005).
  • The presence of delusions mainly related to their therapists or with new technologies.
  • Hearing, vision or motor impairment that makes it impossible to operate a smartphone.
  • Intellectual Developmental Disability.

Sites / Locations

  • Hospital Santa Creu i Sant Pau

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Unified Protocol

Arm Description

The psychotherapy Unified Protocol for Transdiagnostic Treatment of Emotional Disorders.

Outcomes

Primary Outcome Measures

Technology Acceptance Model Scale (TAM)
Degree of acceptance of the digital solution and the intervention delivered. The scale provides scores in 8 dimensions: Perceived Usefulness (score ranges from 5 to 35), Perceived Ease of Use (score ranges from 6 to 42), Attitude (score ranges from 2 to 14), Facilitators (score ranges from 4 to 28), Barriers (score ranges from 2 to 14), Subjective Norm (score ranges from 3 to 21), Intention to Use (score ranges from 1 to 7) and Habits (score ranges from 2 to 14). As much the response trend is located in the positive pole for most of the items, higher acceptability.
User experience questionnaire
A questionnaire ad hoc will be created where the degree of usability and lived experience after using the digital solution will be measured. This scale has not cut off points. Higher values mean higher usability.
Client Satisfaction Questionnaire (CSQ-8)
The opinions and conclusions about the digital solution delivered will be asked. The scale has not cut off points. Higher values mean higher satisfaction.

Secondary Outcome Measures

Positive and Negative Syndrome Scale (PANSS)
Positive, negative and general symptoms of schizophrenia will be assessed. There are not cut off points, direct scores are converted to percentiles. Higher values mean higher presence of positive, negative and general symptoms.
Calgary Depresion Scale for Schizophrenia (CDS)
The level of depression severity in schizophrenia will be assessed. Cut off points: 0-5, no depression; 6-27, depression.
Beck Anxiety Inventory
The level of anxiety will be assessed.
Clinical Global Impression
The severity of positive, negative, depressive and cognitive symptoms and the overall severity of the disorder will be evaluated.
NEO Five-Factor Inventory
Measurement of personality traits.
Toronto Alexithymia Scale
Measurement of alexithymia personality trait.
Global Assessment Functioning
The overall functioning of the patient will be evaluated.
Personal and Social Performance scale
The specific functioning in 4 main areas will be evaluated.
EuroQol-5 Dimensions-5 Levels
Measurement of quality of life according to the patient's perception.
Adherence to Refills and Medications Scale
Measurement of adherence to pharmacological treatment in multiple pathological patients.
Boston University Empowerment Scale
Measurement of the personal construct of empowerment.
Questionnaire about the Process of Recovery
Measurement of patient's viewpoint about recovery from psychosis.
Clinical Outcomes in Routine Evaluation-Outcome Measure
Measurement of the patient's condition based on the dimensions: Subjective well-being, Problems / Symptoms, General functioning, Risk
Functional social support questionnaire (The Duke- UNC-11)
Measurement of perceived functional social support.
Personal Resilience
Measurement of personal resilience.
Visual numerical scale of recovery
Subjective measurement of recovery.
Psychotic Symptom Rating Scales
Measurement of severity of each hallucination's dimensions.
Peterson Delusions Inventory
Assessment of delusional symptoms
Scale Unawareness of Mental Disorders
Assessment of insight into illness.
Beck Cognitive Insight Scale
Assessment of insight into cognitive processes involved in anomalous experiences and misinterpretations.
Overall Depression Severity and Impairment Scale
The level of depression severity will be assessed.
Overall Anxiety Severity and Impairment Scale
The level of anxiety severity will be assessed.
Faces Test
Measurement of capacity to recognise basic and complex emotions in faces.
Emotion Regulation Questionnaire
Measurement of the tendency to regulate emotions.
Difficulties in Emotion Regulation Scale
Measurement of emotional regulation's dimensions.
The Safety Behavior Assessment Form
Assessment of safety behaviour usage.
Five Facet Mindfulness Questionnaire
Assessment of mindfulness' facets.
Involuntary Autobiographical Memory Inventory
Measurement of the frequency of involuntary autobiographical memories and involuntary future thoughts.
Voluntary Control Questions
Measurement of the frequency of voluntary autobiographical memories and future thoughts.
Cognitive Biases Questionnaire for Psychosis
Assessment of bias related to psychosis.
Brief Core Schema Scales
Measurement of schemas.
Brief Experiential Avoidance Questionnaire Questionnaire
Measurement of the functional process to connect with emotions.

Full Information

First Posted
March 16, 2022
Last Updated
April 19, 2022
Sponsor
Grupo Pulso
Collaborators
Hospital de Sant Pau, Nurogames GmbH, Fundació Tic Salut i Social
search

1. Study Identification

Unique Protocol Identification Number
NCT05345977
Brief Title
eMotiph: E-mental Health Solution for Patients With Schizophrenia
Official Title
eMotiph: Smart and Innovative E-mental Health Solution to Manage Patients With Schizophrenia
Study Type
Interventional

2. Study Status

Record Verification Date
April 2022
Overall Recruitment Status
Completed
Study Start Date
June 1, 2021 (Actual)
Primary Completion Date
February 28, 2022 (Actual)
Study Completion Date
February 28, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Grupo Pulso
Collaborators
Hospital de Sant Pau, Nurogames GmbH, Fundació Tic Salut i Social

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Although the main objective of current schizophrenia intervention programs is the reduction of symptoms, its rates are around 36%, and recovery rates are 16.5%. Between 30 and 50% of people with schizophrenia obtain little benefit with conventional therapy. They are considered resistant to treatment. Therefore, the development of innovative evidence-based interventions adjunctive to pharmacological and psychological treatment are necessary for improving results in patients with treatment-resistant schizophrenia (TRS). Studies with digital solutions have shown feasibility, acceptability and even preliminary efficacy data. But no earlier published study has focused on TRS. The eMOTIPH is an innovative solution addressed to TRS and born from the outcomes of the previous study eMOTIPH Part 1 (study of beliefs, needs, and limitations associated with current intervention in TRS patients).
Detailed Description
A prospective non-randomised feasibility trial will be performed. People with a diagnosis of treatment-resistant schizophrenia and their informal caregivers will test the digital mental health solution eMOTIPH for 6 months. Psychiatric treatment and psychological intervention (based on the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders; Farchione et al., 2012) will be delivered to patients. The aim of the study is to evaluate the feasibility, acceptability, usability, satisfaction and perceived quality of life after using the eMOTIPH digital solution.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Schizophrenia
Keywords
mHealth, Treatment resistent schizophrenia

7. Study Design

Primary Purpose
Device Feasibility
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
A prospective non-randomised feasibility trial
Masking
None (Open Label)
Allocation
N/A
Enrollment
7 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Unified Protocol
Arm Type
Experimental
Arm Description
The psychotherapy Unified Protocol for Transdiagnostic Treatment of Emotional Disorders.
Intervention Type
Device
Intervention Name(s)
eMotiph
Intervention Description
Mobile application for patients with schizophrenia.
Primary Outcome Measure Information:
Title
Technology Acceptance Model Scale (TAM)
Description
Degree of acceptance of the digital solution and the intervention delivered. The scale provides scores in 8 dimensions: Perceived Usefulness (score ranges from 5 to 35), Perceived Ease of Use (score ranges from 6 to 42), Attitude (score ranges from 2 to 14), Facilitators (score ranges from 4 to 28), Barriers (score ranges from 2 to 14), Subjective Norm (score ranges from 3 to 21), Intention to Use (score ranges from 1 to 7) and Habits (score ranges from 2 to 14). As much the response trend is located in the positive pole for most of the items, higher acceptability.
Time Frame
Data will be collected immediately after the intervention.
Title
User experience questionnaire
Description
A questionnaire ad hoc will be created where the degree of usability and lived experience after using the digital solution will be measured. This scale has not cut off points. Higher values mean higher usability.
Time Frame
Data will be collected immediately after the intervention
Title
Client Satisfaction Questionnaire (CSQ-8)
Description
The opinions and conclusions about the digital solution delivered will be asked. The scale has not cut off points. Higher values mean higher satisfaction.
Time Frame
Data will be collected immediately after the intervention
Secondary Outcome Measure Information:
Title
Positive and Negative Syndrome Scale (PANSS)
Description
Positive, negative and general symptoms of schizophrenia will be assessed. There are not cut off points, direct scores are converted to percentiles. Higher values mean higher presence of positive, negative and general symptoms.
Time Frame
Change from Baseline Positive and Negative Syndrome Scale at 6 months.
Title
Calgary Depresion Scale for Schizophrenia (CDS)
Description
The level of depression severity in schizophrenia will be assessed. Cut off points: 0-5, no depression; 6-27, depression.
Time Frame
Change from Baseline Calgary Depresion Scale for Schizophrenia at 6 months.
Title
Beck Anxiety Inventory
Description
The level of anxiety will be assessed.
Time Frame
Change from Baseline Beck Anxiety Inventory at 6 months.
Title
Clinical Global Impression
Description
The severity of positive, negative, depressive and cognitive symptoms and the overall severity of the disorder will be evaluated.
Time Frame
Change from Baseline Clinical Global Impression at 6 months.
Title
NEO Five-Factor Inventory
Description
Measurement of personality traits.
Time Frame
Change from Baseline NEO Five-Factor Inventory at 6 months.
Title
Toronto Alexithymia Scale
Description
Measurement of alexithymia personality trait.
Time Frame
Change from Baseline Toronto Alexithymia Scale at 6 months.
Title
Global Assessment Functioning
Description
The overall functioning of the patient will be evaluated.
Time Frame
Change from Baseline Global Assessment Functioning at 6 months.
Title
Personal and Social Performance scale
Description
The specific functioning in 4 main areas will be evaluated.
Time Frame
Change from Baseline Personal and Social Performance scale at 6 months.
Title
EuroQol-5 Dimensions-5 Levels
Description
Measurement of quality of life according to the patient's perception.
Time Frame
Change from Baseline EuroQol-5 Dimensions-5 Levels at 6 months.
Title
Adherence to Refills and Medications Scale
Description
Measurement of adherence to pharmacological treatment in multiple pathological patients.
Time Frame
Change from Baseline Adherence to Refills and Medications Scale at 6 months.
Title
Boston University Empowerment Scale
Description
Measurement of the personal construct of empowerment.
Time Frame
Change from Baseline Boston University Empowerment Scale at 6 months.
Title
Questionnaire about the Process of Recovery
Description
Measurement of patient's viewpoint about recovery from psychosis.
Time Frame
Change from Baseline Questionnaire about the Process of Recovery at 6 months.
Title
Clinical Outcomes in Routine Evaluation-Outcome Measure
Description
Measurement of the patient's condition based on the dimensions: Subjective well-being, Problems / Symptoms, General functioning, Risk
Time Frame
Change from Baseline Clinical Outcomes in Routine Evaluation-Outcome Measure at 6 months.
Title
Functional social support questionnaire (The Duke- UNC-11)
Description
Measurement of perceived functional social support.
Time Frame
Change from Baseline Functional social support questionnaire at 6 months.
Title
Personal Resilience
Description
Measurement of personal resilience.
Time Frame
Change from Baseline Personal Resilience at 6 months.
Title
Visual numerical scale of recovery
Description
Subjective measurement of recovery.
Time Frame
Change from Baseline Visual numerical scale of recovery at 6 months.
Title
Psychotic Symptom Rating Scales
Description
Measurement of severity of each hallucination's dimensions.
Time Frame
Change from Baseline Psychotic Symptom Rating Scales at 6 months.
Title
Peterson Delusions Inventory
Description
Assessment of delusional symptoms
Time Frame
Change from Baseline Peterson Delusions Inventory at 6 months.
Title
Scale Unawareness of Mental Disorders
Description
Assessment of insight into illness.
Time Frame
Change from Baseline Scale Unawareness of Mental Disorders at 6 months.
Title
Beck Cognitive Insight Scale
Description
Assessment of insight into cognitive processes involved in anomalous experiences and misinterpretations.
Time Frame
Change from Baseline Beck Cognitive Insight Scale at 6 months.
Title
Overall Depression Severity and Impairment Scale
Description
The level of depression severity will be assessed.
Time Frame
Data will be collected at baseline, throughout the Unified Protocol sessions and immediately after the intervention.
Title
Overall Anxiety Severity and Impairment Scale
Description
The level of anxiety severity will be assessed.
Time Frame
Data will be collected at baseline, throughout the Unified Protocol sessions and immediately after the intervention.
Title
Faces Test
Description
Measurement of capacity to recognise basic and complex emotions in faces.
Time Frame
Data will be collected at the baseline and immediately after the intervention.
Title
Emotion Regulation Questionnaire
Description
Measurement of the tendency to regulate emotions.
Time Frame
Data will be collected at the baseline and immediately after the intervention.
Title
Difficulties in Emotion Regulation Scale
Description
Measurement of emotional regulation's dimensions.
Time Frame
Data will be collected at the baseline and immediately after the intervention.
Title
The Safety Behavior Assessment Form
Description
Assessment of safety behaviour usage.
Time Frame
Data will be collected at the baseline and and immediately after the intervention.
Title
Five Facet Mindfulness Questionnaire
Description
Assessment of mindfulness' facets.
Time Frame
Data will be collected at the baseline and immediately after the intervention.
Title
Involuntary Autobiographical Memory Inventory
Description
Measurement of the frequency of involuntary autobiographical memories and involuntary future thoughts.
Time Frame
Data will be collected at the baseline and immediately after the intervention.
Title
Voluntary Control Questions
Description
Measurement of the frequency of voluntary autobiographical memories and future thoughts.
Time Frame
Data will be collected at the baseline and immediately after the intervention.
Title
Cognitive Biases Questionnaire for Psychosis
Description
Assessment of bias related to psychosis.
Time Frame
Data will be collected at the baseline and immediately after the intervention.
Title
Brief Core Schema Scales
Description
Measurement of schemas.
Time Frame
Data will be collected at the baseline and immediately after the intervention.
Title
Brief Experiential Avoidance Questionnaire Questionnaire
Description
Measurement of the functional process to connect with emotions.
Time Frame
Data will be collected at the baseline and immediately after the intervention.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age between 18-55 years old. Diagnosis of schizophrenia following the Diagnostic and Statistical Manual of Mental Disorders-5 criteria. Meet criteria for treatment-resistant schizophrenia. Used to information and communication technology and with the physical capability to use them. Exclusion Criteria: Meet criteria for remission according to the Remission of Schizophrenia Working Group (Andreasen et al., 2005). The presence of delusions mainly related to their therapists or with new technologies. Hearing, vision or motor impairment that makes it impossible to operate a smartphone. Intellectual Developmental Disability.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Iluminada Corripio, PhD
Organizational Affiliation
Hospital de Sant Pau
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital Santa Creu i Sant Pau
City
Barcelona
ZIP/Postal Code
08025
Country
Spain

12. IPD Sharing Statement

Learn more about this trial

eMotiph: E-mental Health Solution for Patients With Schizophrenia

We'll reach out to this number within 24 hrs